

**Drug Utilization Review (DUR) Meeting Minutes
September 5, 2018**

Members Present: Katie Kram, Tanya Schmidt, LeNeika Roehrich, Andrea Honeyman, Jesse Rue, Peter Woodrow, Laura Schield, Michael Quast, Michael Booth, Russ Sobotta

Members Absent: Gaylord Kavlie, Zach Marty, Jeffrey Hostetter

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

Old Business

A. Honeyman served as interim Chair and called the meeting to order at 1:15 p.m. Chair A. Honeyman asked for a motion to approve the minutes of the June meeting. K. Kram moved that the minutes be approved and L. Roehrich seconded the motion. Chair A. Honeyman called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Announcements

Jesse Rue has been appointed to the North Dakota Medicaid DUR Board. The current DUR Board Chair position is now open. The election of a new chair will take place at the next DUR Board meeting in December.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 2nd quarter of 2018.

PDL Update

A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent 2018 version of the Preferred Drug List was posted. Notable changes included adding a number of topical corticosteroid agents, as well as high cost (>\$3,000) medications to prior authorization required, as well as removing 30 medications from requiring prior authorization.

Second Review of Daxbia, Millipred DP, and Rytary

A motion and second was made at the June meeting to place Daxbia, Millipred DP, and Rytary on prior authorization. The topics were brought up for a second review to be added to the Non-Preferred Dosage Form PA Criteria. There was no public comment. Chair A. Honeyman called for a voice vote and the motion passed with no audible dissent.

Second Review of Dermatophytosis (Tinea Infections) Agents

A motion and second was made at the June meeting to generate prior authorization criteria for biosimilar agents. The topic was brought up for a second review. There was no public comment. Chair A. Honeyman called for a voice vote and the motion passed with no audible dissent.

Second Review of Eosinophilic Asthma Agents

A motion and second was made at the June meeting to place eosinophilic asthma agents on prior authorization. The topics were brought up for a second review. There was no public comment. Chair A. Honeyman called for a voice vote and the motion passed with no audible dissent.

Second Review of Migraine Prophylaxis (CGRP Inhibitors) Agents

A motion and second was made at the June meeting to place Migraine Prophylaxis (CGRP Inhibitors) Agents on prior authorization. The topic was brought up for a second review. Erin Conley of Amgen spoke regarding expected symptom improvement after treatment with Aimovig. Chair A. Honeyman called for a voice vote and the motion passed with no audible dissent.

Sanford Health Plan Update

Danny Weiss, representing Sanford Health Plan, spoke regarding ND Medicaid Expansion. In 2017, there were 20,087 average members per month with 77.2% of members utilizing benefits. The generic fill rate was 86.3%. The top 25 drugs represent 44.5% of total plan cost and 6 of the top 25 drugs were specialty drugs. Advanced Opioid Management Activity was also discussed, highlighting claims processing edits put in place as well as targeted interventions, resulting in an overall 19.6% reduction in patients receiving opioids in the 1st half of 2018, as compared to the first two quarters of 2017.

New Business

Glyburide and Avandia

T. DeRuiter and A. Murphy reviewed glyburide and rosiglitazone containing products with the Board. A motion was made by K. Kram to create this new PA criteria class and manage these medications through prior authorization. The motion was seconded by T. Schmidt. This topic will be reviewed at the next meeting

Lucemyra

T. DeRuiter and B. Joyce reviewed Lucemyra with the Board. A motion was made by T. Schmidt to manage the medications through prior authorization. The motion was seconded by L. Schield. This topic will be reviewed at the next meeting

Palynziq

T. DeRuiter and B. Joyce reviewed Palynziq with the Board. A motion was made by P. Woodrow to manage the medication through prior authorization. The motion was seconded by T. Schmidt. This topic will be reviewed at the next meeting

Roxybond

T. DeRuiter and B. Joyce reviewed Roxybond with the Board. A motion was made by T. Schmidt to manage the medication through prior authorization. The motion was seconded by J. Rue. This topic will be reviewed at the next meeting

Siklos

T. DeRuiter and B. Joyce reviewed Siklos with the Board. A motion was made by K. Kram to manage the medication through prior authorization. The motion was seconded by J. Rue. This topic will be reviewed at the next meeting

Utilization Review of Concomitant Sedative/Hypnotic and Benzodiazepine Agents

T. DeRuiter presented data on the current utilization of sedative/hypnotics in the fee-for-service Medicaid population. Data points included the incidence of therapeutic duplication with benzodiazepine and or sedative agents, drilled down to most commonly duplicated agents and regimen.

Update on CAR T-cell Therapies

T. DeRuiter presented on the available chimeric antigen receptor T-cell therapies currently available. The presentation included which agents were available and their indications for use, as well as a discussion on how the agents are prepared and elicit their therapeutic effects.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. P. Woodrow moved to approve the new criteria and T. Schmidt seconded the motion. The motion passed with no audible dissent.

Adjournment and Upcoming Meeting Date

Interim Chair A. Honeyman adjourned the meeting at 2:35 pm. The next DUR Board meeting will be held December 5, 2018 at 1:00 pm at the Heritage Center in Bismarck.